MT2025-36: Phase 2/3 Randomized Study of Tebentafusp as Monotherapy and in Combination with Pembrolizumab Versus Investigator s Choice in HLA-A*02:01-positive Participants with Previously Treated Advanced Melanoma (TEBE-AM)

Status: Recruiting

Eligibility Criteria

Sex: Male or Female
Age Group: 18 years and over
This study is NOT accepting healthy volunteers

Inclusion Criteria:

- unresectable Stage III or Stage IV non-ocular melanoma - may not be able to do physically strenuous activity but able to walk and carry out work of a light or sedentary nature, e.g., light house work, office work - see link to clinicaltrials.gov for complete Inclusion criteria

Exclusion Criteria:

- women who are pregnant or breastfeeding - diagnosis of ocular or metastatic uveal melanoma - history of a another type of cancer - unable to be retreated with pembrolizumab because of a previous severe side effect - significant pulmonary or cardiac disease or impaired lung or cardiac function - known psychiatric or substance abuse disorders - see link to clinicaltrials.gov for complete Exclusion criteria

Conditions & Interventions

Interventions:
Drug: Investigators Choice, Drug: Tebentafusp, Drug: Tebentafusp with Pembrolizumab
Conditions:
Cancer
Keywords:
melanoma, Clinics and Surgery Center (CSC)

More Information

Description: This study is about treatment of Melanoma (a kind of skin cancer) that has spread or cannot be surgically removed and has gotten worse after standard treatments. This study includes patients with melanoma from any part of the body except the eye. The main purpose of this study is to learn if the study medicine (tebentafusp), alone or a combination with pembrolizumab, helps patients with advanced melanoma live longer. The combination of pembrolizumab and tebentafusp used in this study is experimental.
Study Contact: Benjamin Manning - mann0233@umn.edu
Principal Investigator: Benjamin Manning
Phase: PHASE3
IRB Number: SITE00001926